Evidence map›Paper›PMID 27599161›Full record

ArticleEpigenetics2016

Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.

Anneleen Decock, Maté Ongenaert, Bram De Wilde, Bénédicte Brichard, Rosa Noguera, Frank Speleman, Jo Vandesompele

Open access · bronzeAbstract read
In one paragraph

Article in Epigenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Neuroblastoma and the epigenome.Cancer metastasis reviews · 2021
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology.International journal of molecular sciences · 2016
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Anneleen Decocka Center for Medical Genetics, Ghent University , Ghent , Belgium.
Maté Ongenaerta Center for Medical Genetics, Ghent University , Ghent , Belgium.
Bram De Wildea Center for Medical Genetics, Ghent University , Ghent , Belgium.
Bénédicte Brichardd Cliniques Universitaires Saint-Luc, Université Catholique de Louvain , Brussels , Belgium.
Rosa Noguerae Department of Pathology , Medical School, University of Valencia, and Health Research Institute INCLIVA , Valencia , Spain.
Frank Spelemana Center for Medical Genetics, Ghent University , Ghent , Belgium.
Jo Vandesompelea Center for Medical Genetics, Ghent University , Ghent , Belgium.
Ghent University Hospital · BECancer Research Institute Ghent · BEINCLIVA Health Research Institute · ESUCLouvain · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stage 4S neuroblastoma (NB) is a special type of NB found in infants with metastases at diagnosis and is associated with an excellent outcome due to its remarkable capacity to undergo spontaneous regression. As genomics have not been able to explain this intriguing clinical presentation, we here aimed at profiling the DNA methylome of stage 4S NB to better understand this phenomenon. To this purpose, differential methylation analyses between International Neuroblastoma Staging System (INSS) stage 4S, stage 4 and stage 1/2 were performed, using methyl-CpG-binding domain (MBD) sequencing data of 14 stage 4S, 14 stage 4, and 13 stage 1/2 primary NB tumors (all MYCN non-amplified in order not to confound results). Stage 4S-specific hyper- and hypomethylated promoters were determined and further characterized for genomic localization and function by cytogenetic band enrichment, gene set enrichment, transcription factor target enrichment and differential RNA expression analyses. We show that specific chromosomal locations are enriched for stage 4S differentially methylated promoters and that stage 4S tumors show characteristic hypermethylation of specific subtelomeric promoters. Furthermore, genes involved in important oncogenic pathways, in neural crest development and differentiation, and in epigenetic processes are differentially methylated and expressed in stage 4S tumors. Based on these findings, we describe new biological mechanisms possibly contributing to the stage 4S-specific tumor biology and spontaneous regression. In conclusion, this study is the first to describe the highly characteristic stage 4S DNA methylome. These findings will open new avenues to further unravel the NB pathology in general and stage 4S disease specifically.

Indexed as

DNA methylationmethyl-CpG-binding domain (MBD) sequencingneuroblastomaspontaneous regressionstage 4S (MS)

Identifiers

PMID27599161
PMCPMC5094630
OpenAlexW2517203095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.